Malignant mesothelioma

Pelin, K. (1994). Asbestos-related malignant mesothelioma Tumor cel characteristics and mechanisms m fibre carcinogenesis. Academic diss.. University of Helsinki. 

Baris, Y.I., Simonato, L., Satacci, R, Skidmore, J.W. and Art-vinli, M. (1981). Malignant mesothelioma and radiological chest abnormalities in two villages in central Turkey. Lancet i, 984-987. 

Malignant mesothelioma, described more than 100 years ago, is a comparatively rare tumor that occurs in the pleura and peritoneum, membranes that surround the lungs, line the thoracic cavity, surround the gut, and line the abdominal cavity. The survival time of mesothelioma patients is often less than a year, in spite of chemotherapy and radiotherapy. Combined therapy and surgical resection in cases of early diagnosis, a treatment currently being tested, has produced a few long-term (more than five years) survivors (Ant-man, et ah, 1980 Antman et ah, 1983), usually in cases with peritoneal rather than pleural involvement. 

Mindful that mesotheliomas are rare tumors, publications describing nonasbestos-related malignant mesothelioma have now appeared as more critical pathological diagnostic techniques have focused on this particular cancer (Peterson et al, 1984). There are cases of juvenile mesothelioma (Wasser-... 

Antman, K. H. (1981). Clinical presentation and natural history of benign and malignant mesothelioma. Semin. Oncol. 8 313—320. 

Artvinli, M., and Y. I. Baris (1979). Malignant mesotheliomas in the Anatolian region of Turkey epidemiologic study. J. Natl. Cancer Inst. 63 17—22. 

Hillerdal, G. (1983). Malignant mesothelioma 1982 review of 4710 published cases. Br. Dis. Chest 77 321. 

Mow e, G., B. Gylseth, F. Hartveit, and V. Skaug (1985). Fiber concentration in lung tissue of patients with malignant mesothelioma. A case-control study. Cancer 56 1089—1093. 

Feng M, Zhang J, Anver M et al (2011) In vivo imaging of hmnan malignant mesothelioma grown orthotopicaUy in the peritoneal cavity of nude mice. J Cancer 2 123-131... 

Mohr S, Bottin MC, Lannes B et al. Microdissection, mRNA amplification, and microarray a study of pleural mesothelial and malignant mesothelioma cells. Biochimie 2004 86 13-19. 

Comin, C. E., Anichini, C., Boddy, V, Novelli, L., and Dini, S. 2000. MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. Histopathology 36 26-31. 

Sterman, D. H., Treat, J., Litzky, L. A., Amin, K. M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J. M., Albelda, S. M. and Kaiser, L. R. (1998). Adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir gene therapy in patients with localized malignancy Results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9, 1083-1092. 

Leong AS-Y, Parkinson R, Milios J. Thick cell membranes revealed by immunocytochemical staining. A clue to the diagnosis of malignant mesothelioma. 

Leong AS-Y, Stevens MW, Mukheqee TM. Malignant mesothelioma cytologic diagnosis with histologic, immunohistochemical and ultrastructural correlation. Sem. Diagn. Pathol. 1992 9 141-150. 

Utermark T, Alekov A, Lerche H, Abramowski V, Giovannini M, Hanemann CO (2003) Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells. Cancer 97 1955-1962... 

Pulmonary gene therapy is attractive for the treatmment of chronic bronchitis, cystic fibrosis, a-1 antitrypsin deficiency, familial emphysema, asthma, pulmonary infections, surfactant deficiency, pulmonary hypertension, lung cancer, and malignant mesothelioma. The pulmonary endothelium may act as a bioreactor for the production and secretion of therapeutic proteins, such as clotting factors and erythropoietin into the blood circulation. There is a potential benefit for acquired lung diseases, as well as cancers, to be controlled and possibly treated by expression of cytokines, surfactant, antioxidant enzymes, or mucoproteins within lung cells. 

McDonald and McDonald 1980 Voisin et al. 1994). As with other asbestos-related respiratory health effects, asbestos-induced mesothelioma appears to have a long latent period of development. For example, Anderson et al. (1976) described two cases of women who presumably experienced household contact with asbestos as children, when their fathers worked with asbestos, and developed clinically detected pleural mesothelioma more than 30 years later. In a review of 1,105 cases of malignant mesotheliomas associated with occupational exposure to asbestos, Lanphear and Buncher (1992) reported that 99% had a latent period >15 years, and calculated a median latent period of 32 years. 

Testa, JR Fox Chase Cancer Center, Philadelphia, PA Molecular genetic alterations in malignant mesothelioma NCI... 

AisnerJ. 1989. Therapeutic approach to malignant mesothelioma. Chest 96(Suppl 1) 95S-97S... 

Apostolou S, De Rienzo A, Murthy SS, et al. 1999. Absence of BCLIO mutations in human malignant mesothelioma. Cell 97 684-686. 

Ascoli V, Facciolo F, Rahimi S, et al. 1996. Concomitant malignant mesothelioma of the pleura, peritoneum, and tunica vaginalis testis. Diagn Cytopathol 14 243-248. 

Ascoli V, Scalxo CC, Facciolo F, et al. 1996. Malignant mesothelioma in Rome, Italy 1980-1995. A retrospective study of 79 patients. Tumori 82 526-532. 

---